Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55

  • Filters activated: Cancer. Clear all to show 58 items.

Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.

Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K.

Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.


Tat-Tagged and Folate-Modified N-Succinyl-chitosan (Tat-Suc-FA) Self-assembly Nanoparticle for Therapeutic Delivery OGX-011 to A549 Cells.

Yan C, Gu J, Jing H, Taishi J, Lee RJ.

Mol Pharm. 2017 Jun 5;14(6):1898-1905. doi: 10.1021/acs.molpharmaceut.6b01167. Epub 2017 May 9.


A population pharmacokinetic meta-analysis of custirsen, an antisense oligonucleotide, in oncology patients and healthy subjects.

Edwards AY, Elgart A, Farrell C, Barnett-Griness O, Rabinovich-Guilatt L, Spiegelstein O.

Br J Clin Pharmacol. 2017 Sep;83(9):1932-1943. doi: 10.1111/bcp.13287. Epub 2017 May 2.


Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.

Chi KN, Higano CS, Blumenstein B, Ferrero JM, Reeves J, Feyerabend S, Gravis G, Merseburger AS, Stenzl A, Bergman AM, Mukherjee SD, Zalewski P, Saad F, Jacobs C, Gleave M, de Bono JS.

Lancet Oncol. 2017 Apr;18(4):473-485. doi: 10.1016/S1470-2045(17)30168-7. Epub 2017 Mar 8.


Clusterin as a therapeutic target.

Wilson MR, Zoubeidi A.

Expert Opin Ther Targets. 2017 Feb;21(2):201-213. doi: 10.1080/14728222.2017.1267142. Epub 2016 Dec 16. Review.


Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model.

Nishikawa M, Miyake H, Gleave M, Fujisawa M.

Target Oncol. 2017 Feb;12(1):69-79. doi: 10.1007/s11523-016-0448-3.


Metastasis: Resistance fighters.

Savage N.

Nature. 2015 Dec 17;528(7582):S128-9. doi: 10.1038/528S128a. No abstract available.


The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target.

Muhammad LA, Saad F.

Expert Rev Anticancer Ther. 2015;15(9):1049-61. doi: 10.1586/14737140.2015.1064769. Review. Erratum in: Expert Rev Anticancer Ther. 2016;16(1):131.


Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma.

Xiu P, Dong XF, Li XP, Li J.

World J Gastroenterol. 2015 Jul 21;21(27):8262-70. doi: 10.3748/wjg.v21.i27.8262. Review.


Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.

Rabinovich-Guilatt L, Elgart A, Erisson L, Willsie SK, Tessler S, Barnett-Griness O, Pande A, Spiegelstein O.

Br J Clin Pharmacol. 2015 Sep;80(3):436-45. doi: 10.1111/bcp.12633. Epub 2015 Jun 22.


Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.

Wang C, Jin G, Jin H, Wang N, Luo Q, Zhang Y, Gao D, Jiang K, Gu D, Shen Q, Huo X, Hu F, Ge T, Zhao F, Chu W, Shu H, Yao M, Cong W, Qin W.

Oncotarget. 2015 Feb 20;6(5):2903-16.


Clusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survival.

Zhang F, Kumano M, Beraldi E, Fazli L, Du C, Moore S, Sorensen P, Zoubeidi A, Gleave ME.

Nat Commun. 2014 Dec 12;5:5775. doi: 10.1038/ncomms6775.


Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.

Lamoureux F, Baud'huin M, Ory B, Guiho R, Zoubeidi A, Gleave M, Heymann D, Rédini F.

Oncotarget. 2014 Sep 15;5(17):7805-19.


Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.

Blumenstein B, Saad F, Hotte S, Chi KN, Eigl B, Gleave M, Jacobs C.

Cancer Med. 2013 Aug;2(4):468-77. doi: 10.1002/cam4.93. Epub 2013 May 28.


The mechanism of DAB2IP in chemoresistance of prostate cancer cells.

Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao G, Fazli L, Gleave M, He D, Boothman DA, Hsieh JT.

Clin Cancer Res. 2013 Sep 1;19(17):4740-9. doi: 10.1158/1078-0432.CCR-13-0954. Epub 2013 Jul 9.


Potential use of custirsen to treat prostate cancer.

Higano CS.

Onco Targets Ther. 2013 Jun 25;6:785-97. doi: 10.2147/OTT.S33077. Print 2013.


Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability.

Matsumoto H, Yamamoto Y, Shiota M, Kuruma H, Beraldi E, Matsuyama H, Zoubeidi A, Gleave M.

Cancer Res. 2013 Aug 15;73(16):5206-17. doi: 10.1158/0008-5472.CAN-13-0359. Epub 2013 Jun 20.


Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments.

Zhang TY, Agarwal N, Sonpavde G, DiLorenzo G, Bellmunt J, Vogelzang NJ.

Curr Urol Rep. 2013 Jun;14(3):174-83. doi: 10.1007/s11934-013-0322-0.


Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.

Shiota M, Yokomizo A, Fujimoto N, Kuruma H, Naito S.

Curr Cancer Drug Targets. 2013 May;13(4):444-59. Review.


Supplemental Content

Loading ...
Support Center